Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 225Ac-AKY-1189 |
| Synonyms | |
| Therapy Description |
225Ac-AKY-1189 is a radioconjugate comprising the radionuclide actinium-225 linked to the Nectin-4-targeted antibody AKY-1189, which delivers radiation to Nectin-4-expressing tumor cells, potentially resulting in antitumor activity (Eur J Cancer 211 (2024): 114641, Eur J Cancer 211 (2024): 114539). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 225Ac-AKY-1189 | [225Ac]-AKY-1189 | NECTIN4 Antibody 11 | 225Ac-AKY-1189 is a radioconjugate comprising the radionuclide actinium-225 linked to the Nectin-4-targeted antibody AKY-1189, which delivers radiation to Nectin-4-expressing tumor cells, potentially resulting in antitumor activity (Eur J Cancer 211 (2024): 114641, Eur J Cancer 211 (2024): 114539). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07020117 | Phase I | 225Ac-AKY-1189 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Recruiting | USA | 0 |